{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:46Z","timestamp":1792789666696,"version":"4.5.0"},"reference-count":77,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Research and Development","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Geron Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Acute myeloid leukemia (AML) is a heterogeneous disease with limited treatment options. New therapies with novel mechanisms of action are needed. Telomerase and BCL-2 are overexpressed in AML and correlate with disease severity and poor prognosis, suggesting dual targeting may be beneficial. Methods: We evaluated the effect of imetelstat, a telomerase inhibitor, in combination with venetoclax, a BCL-2 inhibitor, in AML cell lines, AML patient-derived samples, and in a MOLM-13 AML xenograft model. Results: In AML cell lines and patient samples, imetelstat plus venetoclax demonstrated dose-dependent synergistic activity to induce apoptosis. Studying AML patient samples ex vivo showed the effect is preferentially in CD34+ leukemic cells, and not in lymphocytes. The synergy induced by venetoclax plus imetelstat was stronger than venetoclax plus hypomethylating agents in AML cell lines. The in vivo MOLM-13 AML xenograft model demonstrated that imetelstat plus venetoclax prolonged survival of tumor-bearing mice compared to either agent alone. Forty percent of mice in the combination group were still alive eighty days after the end of treatment, whereas all mice in the single-agent groups succumbed to disease within two weeks. Mechanisms of synergy elicited by the combination were further illustrated through reduction of hTERT expression and telomerase activity, decreases in the interaction of BCL-2 with BAX, and enhanced mitochondrial dysfunction via loss of mitochondrial membrane potential, and these led to marked increases in the intrinsic mitochondrial apoptosis pathway in AML cells. Conclusions: This study supports the clinical evaluation of imetelstat plus venetoclax for the treatment of AML in the Phase 1 IMAGINE trial (NCT07320235).<\/jats:p>","DOI":"10.3390\/jcm15197399","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:36:07Z","timestamp":1790166967000},"page":"7399","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models"],"prefix":"10.3390","volume":"15","author":[{"given":"Fei","family":"Huang","sequence":"first","affiliation":[{"name":"Geron Corporation, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Rusbuldt","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA 19477, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopoldo","family":"Luistro","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, LLC, Spring House, PA 19477, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Colton","sequence":"additional","affiliation":[{"name":"Geron Corporation, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eid","sequence":"additional","affiliation":[{"name":"Geron Corporation, Foster City, CA 94404, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute myeloid leukemia: A comprehensive review and 2016 update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saultz, J.N., and Garzon, R. (2016). Acute myeloid leukemia: A concise review. J. Clin. Med., 5.","DOI":"10.3390\/jcm5030033"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Geissler, K., Mehta, P., Montesinos, P., and Venditti, A. (2025). Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: Perspectives from a European expert panel. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1642472"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e438662","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2275","article-title":"Telomerase and cancer therapeutics","volume":"8","author":"Harley","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.2174\/092986706778521887","article-title":"Telomerase inhibition in cancer therapeutics: Molecular-based approaches","volume":"13","author":"Cunningham","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2011.09022.x","article-title":"Telomere dysfunction and its role in haematological cancer","volume":"156","author":"Jones","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nrc.2016.55","article-title":"New prospects for targeting telomerase beyond the telomere","volume":"16","author":"Arndt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Robinson, N.J., and Schiemann, W.P. (2022). Telomerase in cancer: Function, regulation, and clinical translation. Cancers, 14.","DOI":"10.3390\/cancers14030808"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"S\u00e9gal-Bendirdjian, E., and Geli, V. (2019). Non-canonical roles of telomerase: Unraveling the imbroglio. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00332"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101543","DOI":"10.1016\/j.redox.2020.101543","article-title":"Non-canonical functions of Telomerase Reverse Transcriptase\u2014Impact on redox homeostasis","volume":"34","author":"Rosen","year":"2020","journal-title":"Redox Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/sj.onc.1208760","article-title":"Lipid modification of GRN163, an N3\u2032\u2192P5\u2032 thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition","volume":"24","author":"Herbert","year":"2005","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.stem.2014.11.010","article-title":"Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy","volume":"15","author":"Bruedigam","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1038\/bcj.2016.13","article-title":"Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis","volume":"6","author":"Tefferi","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.20.01895","article-title":"Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study","volume":"39","author":"Steensma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(23)01724-5","article-title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): A multinational, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Platzbecker","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1056\/NEJMoa1503479","article-title":"Telomerase inhibitor imetelstat in patients with essential thrombocythemia","volume":"373","author":"Baerlocher","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","unstructured":"Geron Corporation (2025). RYTELO\u00ae (Imetelstat) Summary of Product Characteristics, Geron Corporation."},{"key":"ref_23","unstructured":"Geron Corporation (2024). RYTELO\u00ae (Imetelstat) for Injection, for Intravenous Use, Geron Corporation. Package insert."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wei, Y., Cao, Y., Sun, R., Cheng, L., Xiong, X., Jin, X., He, X., Lu, W., and Zhao, M. (2020). Targeting Bcl-2 proteins in acute myeloid leukemia. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.584974"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","article-title":"Venetoclax-based therapies for acute myeloid leukemia","volume":"32","author":"Guerra","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_30","unstructured":"(2016). VENCLEXTA\u00ae (Venetoclax Tablets), for Oral Use, AbbVie Inc.. Package Insert."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1038\/s41375-025-02730-3","article-title":"Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model","volume":"39","author":"Venditti","year":"2025","journal-title":"Leukemia"},{"key":"ref_32","first-page":"493","article-title":"Real world experience of azacitidine + venetoclax in acute myeloid leukemia rigorously following management guidelines from clinical trial","volume":"149","author":"Sedaki","year":"2026","journal-title":"Acta Haematol."},{"key":"ref_33","first-page":"684","article-title":"Telomerase reverse transcriptase contains a BH3-like motif and interacts with BCL-2 family members","volume":"41","author":"Jin","year":"2018","journal-title":"Mol. Cells"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Palamarchuk, A.I., Kovalenko, E.I., and Streltsova, M.A. (2023). Multiple actions of telomerase reverse transcriptase in cell death regulation. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041091"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"14183","DOI":"10.1074\/jbc.272.22.14183","article-title":"Bcl-2 modulates telomerase activity","volume":"272","author":"Mandal","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/sj.cdd.4401670","article-title":"Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function","volume":"12","author":"Rizzo","year":"2005","journal-title":"Cell Death Differ."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ceb.2003.10.004","article-title":"Bcl-2-family proteins and the role of mitochondria in apoptosis","volume":"15","author":"Kuwana","year":"2003","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1093\/nar\/gku439","article-title":"Quantitative telomerase enzyme activity determination using droplet digital PCR with single cell resolution","volume":"42","author":"Ludlow","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nprot.2006.239","article-title":"Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol","volume":"1","author":"Herbert","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.exphem.2013.03.008","article-title":"Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia","volume":"41","author":"Palma","year":"2013","journal-title":"Exp. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17225","DOI":"10.1074\/jbc.C900590199","article-title":"Bcl-2 inhibits a Fas-induced conformational change in the Bax N terminus and Bax mitochondrial translocation","volume":"275","author":"Murphy","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_45","first-page":"18","article-title":"Timing your apoptosis assays","volume":"16","author":"Sundquist","year":"2006","journal-title":"Cell Notes"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","article-title":"The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages","volume":"181","author":"Dzhagalov","year":"2008","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4049\/jimmunol.165.3.1191","article-title":"Lineage-specific telomere shortening and unaltered capacity for telomerase expression in human T and B lymphocytes with age","volume":"165","author":"Son","year":"2000","journal-title":"J. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/leu.2017.78","article-title":"Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis","volume":"31","author":"Mosoyan","year":"2017","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/febs.14186","article-title":"Bax, Bak and beyond\u2014Mitochondrial performance in apoptosis","volume":"285","year":"2018","journal-title":"FEBS J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e70076","DOI":"10.1111\/cts.70076","article-title":"Imetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science","volume":"17","author":"Lennox","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does In Vitro Potency Predict Clinically Efficacious Concentrations?","volume":"108","author":"Hjorth","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic. Clin. Pharm."},{"key":"ref_53","first-page":"1768","article-title":"Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia","volume":"108","author":"Ruokoranta","year":"2023","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27696","DOI":"10.1038\/srep27696","article-title":"Targeting MCL-1\/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Roell, K.R., Reif, D.M., and Motsinger-Reif, A.A. (2017). An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00158"},{"key":"ref_56","first-page":"3931","article-title":"A novel telomerase template antagonist (GRN163) as a potential anticancer agent","volume":"63","author":"Asai","year":"2003","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lederer, S., Dijkstra, T.M.H., and Heskes, T. (2018). Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00031"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"Cokol","year":"2011","journal-title":"Mol. Syst. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Greger, L.M., Greger, C., Hiller, K.A., and Maisch, T. (2025). Optimal Effective Concentration Combinations and synergy evaluations for binary antimicrobial combinations in vitro. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1645341"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chatzilygeroudi, T., Karantanos, T., and Pappa, V. (2025). Unraveling venetoclax resistance: Navigating the future of HMA\/venetoclax-refractory AML in the molecular era. Cancers, 17.","DOI":"10.3390\/cancers17091586"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Garciaz, S., Hospital, M.A., Collette, Y., and Vey, N. (2024). Venetoclax resistance in acute myeloid leukemia. Cancers, 16.","DOI":"10.3390\/cancers16061091"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Barwe, S.P., Huang, F., Kolb, E.A., and Gopalakrishnapillai, A. (2022). Imetelstat induces leukemia stem cell death in pediatric acute myeloid leukemia patient-derived xenografts. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071923"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2024-206473","article-title":"Overcoming Ven\/Aza resistance through imetelstat-mediated lipophagy in acute myeloid leukemia","volume":"144","author":"Bruedigam","year":"2024","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s43018-023-00653-5","article-title":"Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia","volume":"5","author":"Bruedigam","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: From apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1182\/bloodadvances.2025018090","article-title":"Rapid loss of viability in acute myeloid leukemia cells upon telomerase inactivation","volume":"10","author":"Aquilanti","year":"2026","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1038\/sj.onc.1209487","article-title":"hTERT: A novel endogenous inhibitor of the mitochondrial cell death pathway","volume":"25","author":"Massard","year":"2006","journal-title":"Oncogene"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/0008-5472.CAN-10-1588","article-title":"hTERT overexpression alleviates intracellular ROS production, improves mitochondrial function, and inhibits ROS-mediated apoptosis in cancer cells","volume":"71","author":"Indran","year":"2011","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1751-2980.2010.00433.x","article-title":"Knockdown of hTERT by SiRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2","volume":"11","author":"Zhong","year":"2010","journal-title":"J. Dig. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies","volume":"28","author":"Bogenberger","year":"2014","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1242\/jcs.019372","article-title":"Telomerase does not counteract telomere shortening but protects mitochondrial function under oxidative stress","volume":"121","author":"Ahmed","year":"2008","journal-title":"J. Cell Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/ATVBAHA.109.185546","article-title":"Mitochondrial telomerase reverse transcriptase binds to and protects mitochondrial DNA and function from damage","volume":"29","author":"Haendeler","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ccell.2017.11.003","article-title":"Synthetic lethality of combined Bcl-2 inhibition and p53 activation in AML: Mechanisms and superior antileukemic efficacy","volume":"32","author":"Pan","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/1541-7786.MCR-17-0772","article-title":"Transient telomerase inhibition with imetelstat impacts DNA damage signals and cell-cycle kinetics","volume":"16","author":"Thompson","year":"2018","journal-title":"Mol. Cancer Res."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7399\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:29:50Z","timestamp":1790310590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":77,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197399"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197399","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}